Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein

• US 20020054914A1
• Filed: 08/17/2001
• Published: 05/09/2002
• Est. Priority Date: 02/03/1999
• Status: Abandoned Application

• Current Assignee: CaPtivate Pharmaceuticals, LLC
• Original Assignee: CaPtivate Pharmaceuticals, LLC
• Inventors: Morcol, Tulin, Bell, Steve J.D.
• Application Number:
  US09/932,503
• Publication Number:
  US 20020054914A1
• Time in Patent Office: Days
• US Class Current: 424/491
• CPC Class Codes: A61K 2039/55505 Inorganic adjuvants
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1676 having a drug-free core with discrete complete coating layer containing drug adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921
• CPC Class Codes: A61K 9/5052 Proteins, e.g. albumin
• CPC Class Codes: A61K 9/5073 having two or more different coatings optionally including drug-containing subcoatings
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61K 9/5115 Inorganic compounds
• CPC Class Codes: A61K 9/5169 Proteins, e.g. albumin, gelatin
• CPC Class Codes: A61K 9/5192 Processes
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates generally to an oral drug delivery system which incorporates a therapeutic bioactive agent with biodegradable calcium phosphate particles, the particles then encapsulated by casein. The resulting particles provide a carrier designed to protect the therapeutic agent in the harsh, acidic environment of the stomach before releasing the agent into the small intestine. The therapeutic agent may be any therapeutically effective agent, such as a natural isolate or synthetic chemical or biological agent, such as a therapeutic agent, and in particular, may be a protein or a peptide such as insulin. Also incorporated with the particles may be additional surface modifying agents to assist binding, controlled release, or to otherwise modify the particles. The particles generally support the therapeutic agent to form controlled- or sustained-release particles for the oral or mucosal delivery of the therapeutic agent over time, wherein the therapeutic agent is incorporated into the structure of the particle core, disposed on the surface of the particle, or both.

Claims

1. A particle, comprising:

(1) a core, comprising calcium phosphate;

(2) a therapeutic agent associated with the core; and

(3) a layer comprising casein at least partially covering the core.

2. The particle of claim 1, wherein the therapeutic agent is selected from the group consisting of insulin, Alpha-1-Antitrypsin, Human Growth Hormone (HGH);

Erythropoeitin (EPO), Steroids, drugs to treat osteoporosis, blood coagulation factors, anti-cancer drugs, antibiotics, lipase, garanulocyte-colony stimulating factor (G-CSF), Beta-Blockers, anti-asthma, anti-sense oligonucleotides, therapeutic antibodies, DNase enzyme for respiratory diseases, anti-inflammatory drugs, anti-virals, anti-hypertensives, cardiotherapeutics, anti-arrythmia drugs, gene therapies;

diuretics, anti-clotting chemicals, and any combination thereof.

3. The particle of claim 1, wherein the particle size ranges from about 300 nm to about 10 microns.

4. The particle of claim 1, wherein the therapeutic agent is at least partially coated on the outside of the core, at least partially encapsulated within the core, or a combination of both.

5. The particle of claim 1, further comprising a surface modifying agent at least partially coated on the outside of the core, at least partially embedded within the core, or a combination of both.

6. The particle of claim 5, wherein the surface modifying agent is selected from the group consisting of basic sugars, modified sugars, polyethylene glycol, cellobiose, oligonucleotides, carbohydrates, carbohydrate derivatives, macromolecules with carbohydrate-like components, and combinations thereof.

7. A therapeutic composition comprising the particle of claim 1 and a pharmaceutically acceptable excipient.

8. The therapeutic composition of claim 7, wherein the therapeutic agent is insulin.

12. A method for delivering a therapeutic amount of a therapeutic agent to a patient in need thereof, comprising orally delivering one or more particles of claim 1.

9. A therapeutic composition suitable for oral delivery of insulin, comprising:

(1) a core comprising calcium phosphate;

(2) insulin and polyethylene glycol associated with the core;

wherein the insulin and polyethylene glycol are at least partially encapsulated within the core;

(3) a capsule comprising casein at least partially covering the core;

wherein the capsule is combined with a pharmaceutically acceptable excipient.

10. A method of preparing one or more particles having calcium phosphate complexed with a therapeutic agent to form a particle, wherein the particle is encapsulated by casein, comprising:

(a) reacting a soluble calcium salt, a soluble phosphate salt, and the therapeutic agent to form a mixture;

(b) dispersing the mixture in a solution of casein.

11. The method of claim 10, wherein the reacting (a) further comprises:

(i) mixing the therapeutic agent with a surface modifying agent; and

(ii) reacting the soluble calcium salt and the soluble phosphate salt with the therapeutic agent and surface modifying agent to form the mixture.